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Effective management of wound exudate is key to promoting successful wound healing 
(White and Cutting, 2006). Wound 
exudate is produced in response to 
a complicated interaction between: 
wound aetiology, wound healing 
physiology, wound environment and 
compounding pathological processes 
(World Union of Wound Healing 
Societies [WUWHS], 2007). However, 
wound fluid is also known to assist 
healing by preventing the drying out 
of the wound bed, aiding migration of 
tissue-repairing cells, providing nutrients 
for cell metabolism and assisting in 
as they are designed to (Thomas, 2008):
8 Maintain a moist environment
8 Provide thermal insulation
8 Manage exudate
8 Allow gaseous exchange
8 Provide a barrier for bacteria
8 Allow atraumatic dressing changes. 
Like many modern wound dressings, 
foam dressings have advantages over 
simple dry gauze (Vermeulen et al, 
2005), as they provide the moist wound 
environment known to be required to 
promote wound healing (Jones, 2005). 
However, one major disadvantage with 
modern wound dressings is the cost 
implications. While cost is an important 
factor to consider in health care today, 
it should not override quality of care 
(Department of Health [DH], 2010). 
Studies have shown that pain, odour 
and exudate impact directly on patient 
quality of life (Vowden and Vowden, 
2003). It is therefore vital that exudate is 
appropriately managed.
Wound dressings account for about 
£116 million of prescribing costs in 
primary care in England each year, 
with foam dressings being one of the 
most commonly prescribed wound 
management products, accounting for 
19% of the total £116 million annual 
spend (National Prescribing Centre, 
2010). Currently, the NHS is facing the 
most significant and complex change 
it has ever seen, while also trying to 
reduce costs and maintain the highest 
The use of advanced wound dressings currently presents a costly burden to the NHS. Subsequently, 
clinicians need to ensure that such dressings are used appropriately and are clinically effective. This article 
discusses the merits of foam dressings within wound care and describes three clinical case reports using 
Advazorb® foam dressings (Advancis Medical) in the treatment of acute/chronic wounds. These foam 
dressings include a range of wound care solutions, which have been found to be clinically effective while 
potentially providing financial benefits without compromising quality of care.
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autolysis (WUWHS, 2007). Therefore, 
the accurate management of exudate 
levels is vital and often at the forefront 
of practitioners’ minds when prescribing 
wound management regimens. 
Dressings have both a prophylactic 
and therapeutic role, by protecting the 
surrounding skin (White and Cutting, 
2003). Excessive fluid needs to be 
... the accurate management 
of exudate levels is vital 
and often at the forefront 
of practitioners’ minds 
when prescribing wound 
management regimens.
removed to ensure that the peri-ulcer 
skin does not become macerated 
or eroded. However, simultaneously, 
dressings need to maintain a moist 
wound environment at the wound 
surface to allow healing to occur. 
Clinicians need to have knowledge, 
experience and tests to determine 
wound aetiology, comorbidities and 
current wound status in order to guide 
management (WUWHS, 2008). 
Following accurate assessment and 
treatment of underlying causes, where 
possible, foam dressings are often utilised 
to manage moderate to high levels of 
exudate. Foam dressings provide many 
of the characteristics of an ideal dressing, 
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standards of care. The NHS White 
Paper Equality and Excellence: liberating 
the NHS (Department of Health (DH), 
2010) and the accompanying paper, From 
Good to the Great (DH, 2009), both set 
clear objectives in terms of quality, cost-
effectiveness and improvement in health 
care and health outcomes.
Advazorb® (Advancis Medical) is a 
comprehensive range of patient-friendly, 
absorbent foam dressings presented in 
non-adhesive and atraumatic silicone 
adhesives.  In the author’s opinion, this 
hydrophilic foam dressing range provides 
an opportunity to reduce cost without 
compromising clinical/quality outcomes, 
and has been specifically designed to 
overcome the complex challenges of 
managing exudate while protecting ‘at 
risk’ fragile skin. Advazorb Silfix® and 
Advazorb Silflo® have a soft silicone 
contact layer, which has been proven to 
protect the surrounding skin, provide 
atraumatic dressing changes and comfort 
during dressing wear (Barrett, 2009; 
Hampton, 2010).
New Advazorb® range 
8 Advazorb non-adhesive foam 
dressings
8 Advazorb Silfix, soft silicone faced 
adhesive foam dressing 
8 Advazorb Silflo, bordered foam 
dressing with soft silicone wound 
contact layer.
The Advazorb range is available in 
both regular thickness for moderate to 
high exudate, and ‘Lite’ versions for light 
to moderately exuding wounds.
There are many foam dressings on 
the market, all of which absorb fluid 
in a variety of ways according to the 
brand. Many have hydropolyers with the 
foam which absorb the fluid into the 
structure of the foam. Additionally, some 
have the capacity to wick horizontally, 
potentially increasing absorbency as the 
fluid is spread through the whole of 
the dressing. Furthermore, some foam 
dressings are able to ‘breathe off ’ the 
moisture that they absorb through a 
permeable backing. This, again has the 
capacity to increase the absorbency of 
the dressing, referred to as the moisture 
vapour transfer rate (MVTR). Some 
foam products have adhesive boarders 
or silicone-lined wound contact layers. 
Thomas (2010) independently 
evaluated the absorbency of market 
leading foams and found that most 
of the foam products examined 
(Allevyn® [Smith and Nephew], Biatain® 
[Coloplast], Mepilex [Mölnlycke Health 
Care], Tielle® [Systagenix], Cutimed® 
Siltec [BSN medical], Medifoam [Biopol] 
and Versiva® [ConvaTec]) were similar 
in terms of absorbency, but had marked 
differences in terms of MVTR and 
retention. He concluded that although 
absorbency is important in foam 
dressing performance, the moisture 
vapour permeability of a dressing plays 
a key role in determining its total fluid-
handling capacity. Advazorb dressings 
has a MVTR rate of 2600–2700g/
m2/24hours and has been proven in 
independent testing to have absorbency 
and fluid retention rates comparable to 
market leading foams (Figure 1).
The absorbency capacity of foam 
dressings directly relates to wear time, as 
once exceeded, the dressing becomes 
saturated and ineffective. There has 
recently been an emergence of super-
absorbent dressings, designed to control 
large volumes of exudate. These new 
dressings have a different action to 
traditional foams, as they are designed 
to swell in size as the dressing absorbs 
exudate. Their fluid-handling capability 
is impressive, providing the practitioner 
with much needed solutions to managing 
wounds with high levels of exudate. 
However, the disadvantages of these 
dressings are that they absorb large 
quantities of fluid which will increase 
weight and bulk as they absorb, this can 
make them uncomfortable to wear. The 
author believes that there is a potential 
that if exudate levels reduce, the super 
absorbent dressings could cause the 
wound bed too become too dry 
resulting in delayed wound healing. Thus, 
for moderate to highly exuding wounds, 
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Figure 1. Independent test data.
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in the author’s clinical experience, foam 
dressings provide the perfect balance 
between fluid-handling capabilities and 
maintaining moist wound healing.
 In this clinical evaluation, the 
Advazorb range has been shown 
to control exudate effectively while 
maintaining a moist wound environment, 
while also being comfortable making 
dressings of difficult areas like the 
malleolus or digits possible. Advazorb 
Silfix promotes wound management 
by providing ideal protection of fragile 
tissue under compression therapy, 
while ensuring that moisture levels 
are maintained at an ideal optimum 
to promote wound healing and pain-
free removal at dressing changes. The 
following cases reports demonstrate the 
use of the dressings in clinical practice.
Case reports
Case one
Mr W presented with a painful leg 
ulcer, which had been present for three 
months. The ulcer appeared to be 
superficial in depth, but the wound bed 
had approximately 90% dehydrated 
slough visible, which was turning into 
eschar (Figure 2). The surrounding skin 
appeared discoloured and fragile. On 
assessment, Mr W had a full complement 
of pulses with an ankle brachial pressure 
index (ABPI) of 0.95 and a normal 
triphasic Doppler tone, indicating no 
problems with peripheral arterial 
disease. However, there were signs of 
venous insufficiency with mild oedema 
and visible varicosities. 
Mr W sometimes complained of 
pain, especially at dressing change. The 
ulcer was diagnosed as being venous 
in origin and he was started on 4-layer 
compression bandaging to reduce 
the venous insufficiency and promote 
healing. Activon™ tulle dressings 
(Advancis Medical) were used to 
rehydrate the slough and eschar. These 
were topped with Advazorb Silfix soft 
silicone faced adhesive foam dressings, 
to ensure that the wound bed was 
kept moist while simultaneously coping 
with any increase in exudate caused 
by the honey rehydrating the wound 
bed. Advazorb Silfix soft silicone is also 
designed to minimise pain and trauma 
at dressing change, thereby ensuring that 
the surrounding fragile skin and newly-
formed granulation tissue is protected. 
Four weeks later the ulcer had 
reduced in size (Figure 3), the wound 
bed showed 100% granulation tissue and 
the surrounding skin appeared healthy. 
Figure 2. Ulcer at presentation.
Figure 3. Mr W’s ulcer at four weeks since referral.
Figure 4. Fully healed after eight weeks  
of treatment.
Figure 5. Infected toe in newly-diagnosed patient 
with diabetes.
Figure 6. 48 hours after treatment with Advazorb.
Figure 7. Complete healing after three weeks  
of treatment.
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will promote an optimum environment 
for healing to occur. It is also important 
to address patients’ needs in terms of 
pain-free dressing removal, prevention 
of leakage and minimal dressing changes. 
In times of stringent financial controls, 
practitioners should embrace new 
products that deliver cost-savings without 
compromising quality of care.
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At this stage, Activon was discontinued 
and Advazorb Silfix was used as a 
primary dressing under compression 
bandaging. Four weeks later the wound 
had healed completely (Figure 4).
Case report two
In this case, Mr B presented acutely with 
an ulcerated painful left great toe of 
two weeks’ duration. There were two 
areas of ulceration which were highly 
exudating (Figure 5). The toe was being 
dressed with non-adherent dressings, 
but these were failing to manage 
the exudate, resulting in extensive 
maceration of the surrounding tissue. Mr 
B had no past medical history and was 
not taking any medication. Blood sugar 
tests revealed elevated levels and he was 
later diagnosed with type two diabetes. 
Oral antibiotics were started and the 
ulcer was dressed with Advazorb non-
adherent foam dressing, due to its 
absorbent properties and added benefit 
of being conformable. Additionally, it 
can be cut to shape for difficult to dress 
anatomical locations such as the toes. 
Within 48 hours there was significant 
improvement as a result of the Advazorb 
dressing absorbing and retaining the 
fluid. The surrounding maceration was 
resolved, the risk of infection reduced 
and progression to healing of the 
ulcerated areas was evident (Figure 6).
 
Three weeks later compete healing 
had been achieved (Figure 7).
The absorbent nature of Advazorb 
ensured that fluid was rapidly absorbed 
and retained within the dressing, thereby 
allowing healing to occur. Effective 
moisture management is an essential 
component of wound management, 
especially when dealing with diabetic 
foot sepsis, where moisture levels, if not 
effectively controlled, can compromise 
the viability of the digit/foot.
Conclusion
Healthcare practitioners should have the 
appropriate skills and training to ensure 
that they understand the importance 
of accurate wound assessment. This, 
combined with knowledge of specific 
wound dressings, will help with 
appropriate dressing selection, which 
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component to promoting 
successful wound healing.
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exudate effectively, while 
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In times of stringent 
financial controls, 
practitioners should 
embrace new products that 
deliver cost-savings without 
compromising quality  
of care.
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